Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1-2% per year. We analysed 176 consecutive patients with IgM MGUS to evaluate risk factors for progression. With a median follow-up of 83 months (1214 person-years), 15 patients (8·5%) progressed to WM (n = 14) or marginal zone lymphoma (n = 1). The rate of progression was 1·32% per year (95% confidence interval [CI] 0·80-2·20). The serum monoclonal protein concentration and the MYD88 mutation were independent risk factors for progression (Hazard ratio [HR] 23·3, 95% CI 2·0-273·3, P = 0·012 and HR 24·4, 95% CI 2·2-275·3, P = 0·010, respectively). The cumulative incidence of progression, while considering death as a competing event, was 11·6% at 5 years and 38·0% at 10 years in MYD88-mutated patients with a serum monoclonal protein of 10 g/l or higher, as compared with 0% at 5 years and 1·1% at 10 years for patients with none or one risk factor. This risk-stratification model is able to identify a subset of patients with IgM MGUS at high risk of progression to WM or LPD who deserve a lifelong follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.16086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Free Light Chain Multiple Myeloma: Atypical Appearance on Serum Immunofixation.
Clin Lab
September 2025
Background: Light chain multiple myeloma (LCMM) is a malignant hematological disease characterized by bone marrow infiltration by tumor plasma cells and the secretion of monoclonal free light chains (κ or λ). It is often di-agnosed through hypogammaglobulinemia detected by serum protein electrophoresis, followed by immunotyping showing a monoclonal band in free light chains. However, the structure of monoclonal light chains can sometimes complicate laboratory findings.
View Article and Find Full Text PDFClinicopathologic Features, Pathogenesis, and Treatment of Monoclonal Gammopathy-Associated Myopathies.
Neurology
October 2025
Department of Neurology, Mayo Clinic, Rochester, MN.
Monoclonal gammopathy-associated myopathies (MGAMs) are rare yet treatable myopathies that occur in association with monoclonal gammopathies. These myopathies include light chain (AL) amyloidosis myopathy, sporadic late-onset nemaline myopathy (SLONM), scleromyxedema with associated myopathy, and newly reported monoclonal gammopathy-associated glycogen storage myopathy (MGGSM), including the vacuolar myopathy with monoclonal gammopathy and stiffness. All these 4 distinct subtypes of MGAMs typically present in patients aged 40 or older, frequently with a subacute onset of rapidly progressive proximal and axial muscle weakness.
View Article and Find Full Text PDFClinical applications of mass spectrometry in multiple myeloma.
Blood Adv
September 2025
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.
Mass spectrometry (MS) is an emerging tool in multiple myeloma that detects and quantifies monoclonal proteins in the peripheral blood with sensitivity several orders of magnitude greater than conventional serum protein electrophoresis and immunofixation. Both intact light chain (top-down) and clonotypic peptide (bottom-up) MS approaches have demonstrated sensitivity comparable to-or even surpassing-BM-based assessments using next generation flow cytometry or sequencing. However, due to the delayed clearance of paraproteins, MS may be less informative for early response assessment, underscoring the need to define the optimal timing for evaluation.
View Article and Find Full Text PDFEngineering a Coiled-Coil Protein for DARPin Presentation as a Potent SARS-CoV-2 Therapeutic.
Biomacromolecules
September 2025
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 950 Atlantic Dr NW, Atlanta, Georgia 30332, United States.
The COVID-19 pandemic has demonstrated the need for rapid, flexible, and readily adaptable treatment options for future pandemic preparedness. Due to the speed at which viruses like SARS-CoV-2 mutate, the customary approach of using highly specific monoclonal antibodies as neutralization therapies is challenging, given their size, production complexity, and cost. Here, we leveraged rational protein design to create fusion proteins from small, antibody-mimetic proteins, Designed Ankyrin Repeat Proteins (DARPins) and a self-assembling hexameric coiled coil (CC-HEX).
View Article and Find Full Text PDFEfficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.
Front Immunol
September 2025
Department of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, China.
Objective: This study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).
Methods: Fifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunological response, renal function and adverse events were assessed throughout the follow-up period between patients receiving obinutuzumab as initial therapy and alternative therapy.